News Related to Bosakitug

Related coverage linked through entity extraction aliases.

Aclaris Therapeutics Details TSLP/ITK Pipeline with Multiple Clinical Readouts Expected in Late 2026

Apr 28, 2026

Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.

AAD 2026 and pipeline updates highlight new atopic dermatitis treatment data

Apr 21, 2026

Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.